Related Experiment Videos
The role of platelets in ischemic stroke
1Department of Molecular and Experimental Medicine, the Scripps Research Institute, Scripps Clinic and Research Foundation, La Jolla, CA 92037, USA.
Neurology
|September 23, 1998
Summary
Platelets play a key role in focal cerebral ischemia and stroke. Antiplatelet agents reduce stroke events but carry a risk of hemorrhage, requiring a balance between efficacy and safety.
Area of Science:
- Neuroscience
- Hematology
- Cardiovascular Medicine
Background:
- Platelets are crucial in hemostasis and thrombosis, contributing to thromboemboli formation.
- Platelet activation is triggered by vascular injury, fibrin deposition, and abnormal surfaces like atheromata.
- Platelet thrombi on atheromata suggest a significant role in stroke pathogenesis.
Purpose of the Study:
- To explore the role of platelets in focal cerebral ischemia.
- To review the efficacy of antiplatelet agents in preventing secondary stroke events.
- To discuss the risk of hemorrhage associated with antiplatelet therapy.
Main Methods:
- Literature review of studies on platelet function in stroke.
- Analysis of clinical trial data for antiplatelet agents (aspirin, aspirin/dipyridamole, ticlopidine, clopidogrel).
- Evaluation of the risk-benefit profile of antiplatelet therapy in ischemic stroke.
Main Results:
- Antiplatelet agents like aspirin significantly reduce ischemic stroke incidence.
- Combined aspirin and dipyridamole, ticlopidine, and clopidogrel are effective in preventing recurrent vascular events.
- All antithrombotic agents pose a risk of symptomatic intracerebral hemorrhage.
Conclusions:
- Platelet physiology is integral to stroke development and prevention.
- Balancing the thrombotic benefits against hemorrhage risks is essential for antiplatelet therapy.
- Further research is needed to elucidate the mechanism of antiplatelet-induced hemorrhage.